U.S., Feb. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07421180) titled 'Maternal Serum Adropin in Placenta Accreta Spectrum' on Feb. 12.
Brief Summary: Aim: To compare maternal serum adropin levels in pregnancies complicated by placenta previa and/or placenta accreta spectrum (PAS) with those of healthy pregnant women and to evaluate the diagnostic value of adropin for predicting placental invasion.
Methods:
This cross-sectional study included 84 singleton pregnancies at >=34 weeks of gestation: 42 women diagnosed with placenta previa and/or PAS and 42 healthy pregnant women who underwent cesarean delivery. Maternal serum adropin levels are measured preoperatively using enzyme-linked immunosorbent ass...